tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

MXCT Stock Latest News

MaxCyte Cancels AIM Market Trading for Common Stock
Company AnnouncementsMaxCyte Cancels AIM Market Trading for Common Stock
15d ago
8K
MXCT
MaxCyte Shareholders Approve Equity Plan Amendment
PremiumCompany Announcements
MaxCyte Shareholders Approve Equity Plan Amendment
22d ago
8K
MXCT
MaxCyte Announces Change in Major Holdings by BlackRock
PremiumCompany Announcements
MaxCyte Announces Change in Major Holdings by BlackRock
29d ago
MXCT
MaxCyte, Oribiotech team on cell therapy manufacturing
PremiumThe Fly
MaxCyte, Oribiotech team on cell therapy manufacturing
30d ago
MXCT
MaxCyte and Ori Biotech Collaborate to Enhance Cell Therapy Manufacturing
PremiumCompany Announcements
MaxCyte and Ori Biotech Collaborate to Enhance Cell Therapy Manufacturing
30d ago
MXCT
MaxCyte Announces Change in Voting Rights Structure
PremiumCompany AnnouncementsMaxCyte Announces Change in Voting Rights Structure
1M ago
MXCT
BlackRock Increases Stake in MaxCyte to 9.98%
Premium
Company Announcements
BlackRock Increases Stake in MaxCyte to 9.98%
1M ago
MXCT
MaxCyte Expands Stock Capital Amidst Strategic Growth
Premium
Company Announcements
MaxCyte Expands Stock Capital Amidst Strategic Growth
1M ago
MXCT
BlackRock Increases Stake in MaxCyte
PremiumCompany Announcements
BlackRock Increases Stake in MaxCyte
1M ago
MXCT
MaxCyte Announces Change in Voting Rights Structure
PremiumCompany Announcements
MaxCyte Announces Change in Voting Rights Structure
1M ago
MXCT
MaxCyte Announces Change in Major Shareholder Voting Rights
PremiumCompany Announcements
MaxCyte Announces Change in Major Shareholder Voting Rights
2M ago
MXCT
MaxCyte Announces Change in Major Holdings by BlackRock
PremiumCompany Announcements
MaxCyte Announces Change in Major Holdings by BlackRock
2M ago
MXCT
BlackRock Increases Stake in MaxCyte, Boosting Voting Rights
PremiumCompany AnnouncementsBlackRock Increases Stake in MaxCyte, Boosting Voting Rights
2M ago
MXCT
BlackRock Increases Stake in MaxCyte to 7.65%
Premium
Company Announcements
BlackRock Increases Stake in MaxCyte to 7.65%
2M ago
MXCT
MaxCyte Announces Change in Major Shareholder Holdings
Premium
Company Announcements
MaxCyte Announces Change in Major Shareholder Holdings
2M ago
MXCT
MaxCyte’s Earnings Call: Navigating Challenges and Opportunities
PremiumCompany Announcements
MaxCyte’s Earnings Call: Navigating Challenges and Opportunities
2M ago
MXCT
MaxCyte Files Form 10-Q for Q1 2025
PremiumCompany Announcements
MaxCyte Files Form 10-Q for Q1 2025
2M ago
MXCT
MaxCyte’s Strategic Growth and Stability: A Buy Rating by Analyst Mark Massaro
PremiumRatings
MaxCyte’s Strategic Growth and Stability: A Buy Rating by Analyst Mark Massaro
2M ago
MXCT
MaxCyte’s Strong Financial Performance and Growth Potential Justify Buy Rating
PremiumRatings
MaxCyte’s Strong Financial Performance and Growth Potential Justify Buy Rating
2M ago
MXCT
MaxCyte’s Strong Execution and Strategic Measures Earns Buy Rating Amid Market Challenges
PremiumRatingsMaxCyte’s Strong Execution and Strategic Measures Earns Buy Rating Amid Market Challenges
2M ago
MXCT
MaxCyte reports Q1 EPS (10c), consensus (10c)
Premium
The Fly
MaxCyte reports Q1 EPS (10c), consensus (10c)
2M ago
MXCT
MaxCyte Reports Q1 2025 Financial Results Amid Revenue Dip
Premium
Company Announcements
MaxCyte Reports Q1 2025 Financial Results Amid Revenue Dip
2M ago
8K
MXCT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >